InsidersTradesSigma
Total declarations
Company
▲ Purchases (14 ops.)
▼ Sales (0 ops.)
Insider track record
Board DirectorDisclosed buys
14
Disclosed sells
0
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
Signal history
Browse the full record of transactions filed by Robbins Wendye, Director. Director active across 1 company, notably RAPT Therapeutics, Inc.. Aggregated, 14 filings have been recorded. Breakdown: 14 buys · 0 sell. Total volume traded: €182k. Activity tracked since 16 June 2021. The latest transaction was filed on 14 March 2023 (Acquisition). Regulator: SEC (Form 4). All data is openly available.
Declarations14 total
1,500 shares@ US$18.7514.4% of flowCommon StockSEC:0001209191-23-019023:0
Ideal exit: 9 Dec 2023 (T+270)
2,000 shares@ US$10.5412.9% of flowCommon StockSEC:0001593968-22-000958:0
Ideal exit: 4 Feb 2023 (T+270)
500 shares@ US$30.708.5% of flowCommon StockSEC:0001593968-21-002279:0
Ideal exit: 15 Jul 2022 (T+270)
500 shares@ US$30.707.3% of flowCommon StockSEC:0001593968-21-002279
Ideal exit: 15 Jul 2022 (T+270)
400 shares@ US$29.696.6% of flowCommon StockSEC:0001593968-21-002276:0
Ideal exit: 10 Jul 2022 (T+270)
400 shares@ US$29.695.6% of flowCommon StockSEC:0001593968-21-002276
Ideal exit: 10 Jul 2022 (T+270)
500 shares@ US$31.11448.5% of flowCommon StockSEC:0001593968-21-002027:0
Ideal exit: 20 May 2022 (T+270)
500 shares@ US$31.11447.3% of flowCommon StockSEC:0001593968-21-002027
Ideal exit: 20 May 2022 (T+270)
100 shares@ US$29.8151.6% of flowCommon StockSEC:0001593968-21-002007:0
Ideal exit: 17 May 2022 (T+270)
100 shares@ US$29.8151.4% of flowCommon StockSEC:0001593968-21-002007
Ideal exit: 17 May 2022 (T+270)
600 shares@ US$30.208.5% of flowCommon StockSEC:0001593968-21-001818
Ideal exit: 3 Apr 2022 (T+270)
600 shares@ US$30.209.9% of flowCommon StockSEC:0001593968-21-001818:0
Ideal exit: 3 Apr 2022 (T+270)
500 shares@ US$31.547.2% of flowCommon StockSEC:0001593968-21-001661
Ideal exit: 13 Mar 2022 (T+270)
500 shares@ US$31.548.5% of flowCommon StockSEC:0001593968-21-001661:0
Ideal exit: 13 Mar 2022 (T+270)
14 of 14 declarations
About Robbins Wendye
Wendye Robbins serves as a Director at RAPT Therapeutics, Inc. She contributes to the company's governance and strategic decision-making. Her experience in the pharmaceutical sector is valuable to the board.
